Claims for Patent: 11,260,047

Summary for Patent: 11,260,047

Title:	Formulations of AG10
Abstract:	The present disclosure provides high-load tablet formulations of AG10 or a pharmaceutically acceptable salt thereof. In some aspects, provided herein are table formulations of AG10 or a pharmaceutically acceptable salt thereof that include at least 40% or more AG10 by weight and at least one pharmaceutical excipient selected from one or more fillers, one or more binders, one or more disintegrants, and one or more lubricants.
Inventor(s):	Jesper Jernelius, Mark Michael MENNING
Assignee:	Eidos Therapeutics Inc
Application Number:	US16/542,737
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,260,047
Patent Claims:	1. A tablet formulation comprising AG10, or a pharmaceutically acceptable salt thereof, and one or more fillers, wherein (a) said tablet formulation comprises at least 40% or more by weight of AG10 or a pharmaceutically acceptable salt thereof; and (b) said one or more fillers comprise a high-grade microcrystalline cellulose characterized by cellulose polymers with (i) spherical morphology and porous structure or (ii) needle-like particle shape. 2. The tablet formulation of claim 1, comprising about 40-85% by weight of AG10 or a pharmaceutically acceptable salt thereof. 3. The tablet formulation of claim 2, comprising about 50-75% by weight of AG10 or a pharmaceutically acceptable salt thereof. 4. The tablet formulation of claim 1, comprising about 50% by weight of AG10 or a pharmaceutically acceptable salt thereof. 5. The tablet formulation of claim 1, comprising about 66.7% by weight of AG10 or a pharmaceutically acceptable salt thereof. 6. The tablet formulation of claim 1, comprising about 75% by weight of AG10 or a pharmaceutically acceptable salt thereof. 7. The tablet formulation of claim 1, wherein said one or more fillers comprise about 1-60% by weight of said tablet formulation. 8. The tablet formulation of claim 7, wherein said one or more fillers comprise about 5-55% by weight of said tablet formulation. 9. The tablet formulation of claim 7, wherein said one or more fillers comprise about 10-50% by weight of said tablet formulation. 10. The tablet formulation of claim 7, wherein said one or more fillers comprise about 15-45% by weight of said tablet formulation. 11. The tablet formulation of claim 1, wherein said one or more fillers further comprise a cellulose derivative or an inorganic salt. 12. The tablet formulation of claim 1, wherein said one or more fillers further comprise silicon dioxide. 13. The tablet formulation of claim 1, further comprising one or more disintegrants, said one or more disintegrants comprise about 1-15% by weight of said tablet formulation. 14. The tablet formulation of claim 13, wherein said one or more disintegrants comprise about 3-8% by weight of said tablet formulation. 15. The tablet formulation of claim 13, wherein said one or more disintegrants comprise about 6% by weight of said tablet formulation. 16. The tablet formulation of claim 13, wherein said one or more disintegrants comprise croscarmellose sodium. 17. The tablet formulation of claim 1, further comprising one or more lubricants, said one or more lubricants comprise about 0.1-8% by weight of said tablet formulation. 18. The tablet formulation of claim 17, wherein said one or more lubricants comprise about 1.5% by weight of said tablet formulation. 19. The tablet formulation of claim 17, wherein said one or more lubricants comprise magnesium stearate. 20. The tablet formulation of claim 1, wherein said tablet formulation is at least 75% dissolved after performance of a dissolution test in a solution of 0.1N HCl at 37±0.5° C. in an Apparatus-II (Paddles) with a paddle speed of about 50 rpm for 10 minutes. 21. The tablet formulation of claim 20, wherein said tablet formulation is at least 85% dissolved after performance of said dissolution test. 22. The tablet formulation of claim 21, wherein said tablet formulation is at least 95% dissolved after performance of said dissolution test. 23. The tablet formulation of claim 20, wherein said dissolution test is performed at least three months after preparation of said tablet formulation. 24. The tablet formulation of claim 1, further comprising a coating agent. 25. The tablet formulation of claim 1, wherein AG10 is the pharmaceutically acceptable salt form of Formula Ia 26. A tablet formulation comprising at least 40% or more by weight of AG10, or a pharmaceutically acceptable salt thereof; a high-grade microcrystalline cellulose filler; an inorganic salt filler; a disintegrant; and a lubricant, wherein said high-grade microcrystalline cellulose is characterized by cellulose polymers (i) with spherical morphology and porous structure or (ii) needle-like particle shape.